SOHO 2023: CLL
Advertisement
Patients with ibrutinib dose reductions after AEs had longer treatments and similar outcomes to those without reductions.
Patients with CLL who relapsed after HSCT and then received venetoclax achieved outcomes consistent with trial data.
The rituximab, fludarabine, and cyclophosphamide regimen appeared to be most effective for overall survival and response.
Data suggest patients with CLL are more anxious when receiving intravenous versus oral treatment.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.